Open AccessInactivated or Live-Attenuated Bivalent Vaccines That Confer Protection against Rabies and Ebola Viruses
Author(s) -
Joseph E. Blaney,
Christoph Wirblich,
Amy B. Papaneri,
Reed F. Johnson,
C. Myers,
Terry L. Juelich,
Michael R. Holbrook,
Alexander N. Freiberg,
John G. Bernbaum,
Peter B. Jahrling,
Jason Paragas,
Matthias J. Schnell
Publication year - 2011
Publication title -
journal of virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.617
H-Index - 292
eISSN - 1070-6321
pISSN - 0022-538X
DOI - 10.1128/jvi.00558-11
Subject(s) - virology , ebola vaccine , biology , rabies , rabies virus , ebola virus , attenuated vaccine , duck embryo vaccine , lyssavirus , vaccination , mononegavirales , rabies vaccine , virus , filoviridae , rhabdoviridae , viral disease , virulence , paramyxoviridae , genetics , gene
The search for a safe and efficacious vaccine for Ebola virus continues, as no current vaccine candidate is nearing licensure. We have developed (i) replication-competent, (ii) replication-deficient, and (iii) chemically inactivated rabies virus (RABV) vaccines expressing Zaire Ebola virus (ZEBOV) glycoprotein (GP) by a reverse genetics system based on the SAD B19 RABV wildlife vaccine. ZEBOV GP is efficiently expressed by these vaccine candidates and is incorporated into virions. The vaccine candidates were avirulent after inoculation of adult mice, and viruses with a deletion in the RABV glycoprotein had greatly reduced neurovirulence after intracerebral inoculation in suckling mice. Immunization with live or inactivated RABV vaccines expressing ZEBOV GP induced humoral immunity against each virus and conferred protection from both lethal RABV and EBOV challenge in mice. The bivalent RABV/ZEBOV vaccines described here have several distinct advantages that may speed the development of inactivated vaccines for use in humans and potentially live or inactivated vaccines for use in nonhuman primates at risk of EBOV infection in endemic areas.